Roth Capital analyst George Kelly initiated coverage of Prenetics (PRE) with a Buy rating and $36 price target The company has “struggled to find its footing” after completing its business combination with SPAC Artisan Acquisition but has “found a winner” in complement brand IM8,” the analyst tells investors in a research note. The firm says IM8 has quickly scaled to over $100M in revenue and has now become management’s sole focus. Roth says IM8’s growth potential is underappreciated at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRE:
- Prenetics management to meet with Benchmark
- Prenetics Sells Europa 3PL Unit to Sharpen Focus on High-Growth IM8 Brand
- Prenetics completes sale of its 3PL distribution business
- Prenetics Lifts Warrant Exchange Participation to 86.7%, Sharply Reducing Potential Dilution
- Prenetics provides update on voluntary warrant exchange program